Skip to Content

Cochlear Ltd Stock Quote COH

Rating as of

Morningstar's Cochlear Ltd Stock Analysis

Valuation
Currency in AUD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

Emerging Markets Show Promise but Cochlear Shares Remain Expensive

Shane Ponraj, CFA Equity Analyst

Business Strategy and Outlook

| Shane Ponraj, CFA |

With a consistent share of roughly 60% across developed markets, Cochlear is the market leader in cochlear implants. Cochlear implants became the standard of care many years ago for children in developed markets with profound hearing loss or deafness. With this market segment largely penetrated, the company is looking elsewhere for growth. Developed market adults are the next primary focus, and emerging-market children after that.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics - COH

Company Profile - COH

Business Description

Cochlear is the leading cochlear implant device manufacturer with around 60% global market share. Developed markets contribute 80% of group revenue where cochlear implants are the standard of care for children with severe to profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, or BAHA, and associated sound processors. In fiscal 2020, 49% of revenue came from the Americas, 35% from EMEA, and 16% from the Asia-Pacific segment.

Contact
1 University Avenue, Macquarie University
Sydney, NSW, 2109, Australia
T +61 294286555
Industry Medical Devices
Most Recent Earnings
Fiscal Year End Jun 30, 2022
Stock Type
Employees 4,000

Related News - COH